Clinical Trial Update: Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update evaluating the combination of nab-paclitaxel and nivolumab in recurrent or metastatic head and neck squamous cell carcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• nivolumab (nivolumab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Metastatic Head-and-neck Squamous-cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING